Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-005711
Filing Date
2024-08-14
Accepted
2024-08-14 17:22:52
Documents
44
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUNE 2024 cns_i10q-063024.htm   iXBRL 10-Q 575029
2 CERTIFICATION cns_ex3101.htm EX-31.1 6897
3 CERTIFICATION cns_ex3102.htm EX-31.2 7022
4 CERTIFICATION cns_ex3201.htm EX-32.1 3267
5 CERTIFICATION cns_ex3202.htm EX-32.2 3232
  Complete submission text file 0001683168-24-005711.txt   3361004

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20240630.xsd EX-101.SCH 24193
7 XBRL CALCULATION FILE cnsp-20240630_cal.xml EX-101.CAL 25737
8 XBRL DEFINITION FILE cnsp-20240630_def.xml EX-101.DEF 131576
9 XBRL LABEL FILE cnsp-20240630_lab.xml EX-101.LAB 277314
10 XBRL PRESENTATION FILE cnsp-20240630_pre.xml EX-101.PRE 231837
46 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-063024_htm.xml XML 343973
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 241209626
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)